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Abstract
A practical method was elaborated for the synthesis of (aminomethylene)bisphosphine oxides comprising the catalyst- and solvent-
free microwave-assisted three-component condensation of primary amines, triethyl orthoformate and two equivalents of
diphenylphosphine oxide. The method is also suitable for the preparation of (aminomethylene)bisphosphonates using
(MeO)2P(O)H/(MeO)3CH or (EtO)2P(O)H/(EtO)3CH reactant pairs and even secondary amines. Several intermediates referring to
the reaction mechanism together with a few by-products could also be identified.
Introduction
Substituted (hydroxymethylene)bisphosphonic acid derivatives
form an important group of drugs used in the treatment of
osteoporosis and related bone diseases [1-3]. In the last decades,
at least three generations of dronic acid derivatives appeared
[4].
(Aminomethylene)bisphosphonic acid derivatives are analo-
gous species, that also have potential bioactivity in bone
diseases, besides they display antibacterial, antiparasitic, anti-
cancer and herbicidal activities [5].
(Aminomethylene)bisphosphonates may be prepared in
different ways [5]. One of the most convenient and widespread
methods is the three-component condensation involving an
amine, an orthoformate and a dialkyl phosphite. Usually,
primary or secondary amines were reacted with an equivalent,
Beilstein J. Org. Chem. 2016, 12, 1493–1502.
1494
Scheme 1: Proposed routes for the three-component condensation
[7].
or a small excess of triethyl orthoformate and 2–7 equivalents
of diethyl phosphite [6-21]. In most cases, the corresponding
acids were the target molecules that were obtained by hydroly-
sis of the esters [15-21]. The use of crown ethers with an NH
unit, or thienopyrimidine amines as starting materials was also
reported [22,23]. The catalyst- and solvent-free methods re-
quired long reaction times and/or a high temperature [6-14,21-
23]. Ionic liquids and a few catalysts were also tried out [24-
27], and the synthesis was also described under microwave
(MW) irradiation [28-32]. However, most of the MW-assisted
syntheses were performed in kitchen ovens [28-30], hence these
results cannot be reproduced.
The mechanism of the three-component condensation has been
investigated by the research group of Krutikov and Kafarski
[6,7]. A detailed proposal is shown in Scheme 1 [7]. The first
step of the condensation is the reaction of the amine with the
orthoformate, in which imine-type intermediates I or II may be
formed. The next step is the nucleophilic addition of diethyl
phosphite to the C=N bond of the imines resulting in phos-
phonates III or IV, respectively. Then, the elimination of an
amine or ethanol and the addition of another unit of diethyl
phosphite may lead to (aminomethylene)bisphosphonates (VI).
If the amine is in predominance over the phosphite in the
reaction, the pathway A is more likely, but if the phosphite is
used in excess, the pathway B comes to the fore.
There are other possibilities to synthesize (aminomethylene)bis-
phosphonates, such as by the reaction of dimethylformamide
diethyl acetal with diethyl phosphite (Scheme 2a) [33], by the
condensation of formamides and diethyl phosphite using 2,6-di-
tert-butyl-4-methylpyridine (DTBMP) as the base, and
trifluoromethanesulfonic anhydride (Tf2O) as the catalyst
(Scheme 2b) [34], or by the reaction of isonitriles with triethyl
phosphite (Scheme 2c) [35,36]. (Aminomethylene)bisphospho-
nates can also be obtained starting from amides, triethyl phos-
phite and phosphorus oxychloride (Scheme 3a) [37], or in the
reaction of amines with diazophosphonate in the presence of a
rhodium catalyst (Scheme 3b) [38].
Scheme 2: Synthetic methods for (aminomethylene)bisphosphonates
I.
(Aminomethylene)bisphosphine oxides are analogous to
(aminomethylene)bisphosphonates, but they are much less
studied. Only a few publications were found, which focus on
their synthesis [33,39-42], however, a three-component conden-
sation has not been described. They can also be prepared
starting from dimethylformamide dimethyl acetal, as in the syn-
thesis of (aminomethylene)bisphosphonates, but in the latter
case a secondary phosphine oxide is the P-reagent [33,39]. In
addition, (aminomethylene)bisphosphine oxides can be synthe-
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Scheme 3: Synthetic methods for (aminomethylene)bisphosphonates II.
Scheme 5: Synthesis of alkylamino- and (phenylaminomethylene)bisphosphine oxides.
sized by the reaction of two molecules of (dialkylamino)(di-
phenylphosphinoyl)chloromethane (Scheme 4a) [40,41], or by
the addition of diphenylphosphine oxide to an isonitrile
(Scheme 4b) [36,42].
Scheme 4: Synthetic methods for (aminomethylene)bisphosphine
oxides.
In this paper, we wish to report the results of our investigations
on the synthetic protocol utilizing the three-component conden-
sations of primary or secondary amines, orthoformates and
>P(O)H species, such as dialkyl phosphites or diphenylphos-
phine oxide, and we aimed at the preparation of new deriva-
tives.
Results and Discussion
Synthesis of alkylamino- and (phenylamino-
methylene)bisphosphine oxides
In the first series of experiments, the condensation of primary
amines, such as butyl-, cyclohexyl- and benzylamine or aniline
with triethyl orthoformate, and 2 equivalents of diphenylphos-
phine oxide at 150 °C for 1 h under MW conditions was studied
(Scheme 5). To avoid the formation of by-products, benzyl-
amine was reacted at a lower temperature of 125 °C (Table 1,
entry 3). The reactions were carried out without any catalyst
and solvent. After column chromatography, the new amino-
methylenebisphosphine oxides 1a–d were obtained in yields of
72–82% (Table 1, entries 1–4).
Table 1: Synthesis of alkylamino- and (phenylaminomethylene)bispho-
sphine oxides 1a–d.
Entry Y T (°C) Yield (%)a
1 Bu 150 82 (1a)
2 c-Hex 150 79 (1b)
3 Bn 125b 72 (1c)
4 Ph 150 80 (1d)
aIsolated yield. bAt 150 °C by-products were formed.
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Scheme 6: Synthesis of (dialkylaminomethylene)bisphosphine oxides.
The condensation of simple secondary amines (diethyl-,
dibutyl-, N-butylmethyl-, N-cyclohexylmethyl-, N-benzyl-
methylamine, N-methylaniline and morpholine) was also inves-
tigated with triethyl orthoformate, and 2 equivalents of
diphenylphosphine oxide (Scheme 6,  Table 2).  The
MW-assisted reactions were performed at 150 °C for 1 h under
solvent- and catalyst-free conditions, and the (dialkyl-amino-
methylene)bisphosphine oxides 2a–g were obtained in yields of
60–85% after column chromatography (Table 2, entries 1–7).
Except for compound 2g, all (aminomethylene)bisphosphine
oxides (2a–f) prepared are new compounds. According to the
literature method [41], 2g was synthesized by the reaction of
two molecules of (diphenylphosphinoyl)morpholino-
chloromethane in the presence of chloroform at 5 °C for 18 h in
a yield of 41% (Scheme 4a). Using the MW-assisted three-
component condensation method, this compound (2g) can be
synthesized without any catalyst and solvent in a short time
(1 h), and in a yield of 85% (Table 2, entry 7).
Table 2: Synthesis of (dialkylaminomethylene)bisphosphine oxides
2a–g.
Entry Y1 Y2 Yield (%)a
1 Et Et 82 (2a)
2 Bu Bu 73 (2b)
3 Bu Me 69 (2c)
4 c-Hex Me 66 (2d)
5 Bn Me 64 (2e)
6 Ph Me 60 (2f)
7 -(CH2)2-O-(CH2)2- 85 (2g)
aIsolated yield.
Synthesis of alkylamino- and (phenylamino-
methylene)bisphosphonates
In the next stage, our method was extended to the synthesis of
alkyl- and (phenylaminomethylene)bisphosphonates by reacting
butyl- and cyclohexylamine or aniline, and triethyl orthofor-
mate with diethyl phosphite under MW irradiation in the
absence of catalyst and solvent (Table 3). First, the condensa-
tion of butylamine, triethyl orthoformate with 2 equivalents of
diethyl phosphite was studied at 125 °C. After a 2 h’s reaction
time, the conversion was 91%, and beside the expected (amino-
methylene)bisphosphonate 3a formed in 81%, the N-ethylated
by-product 4a was formed in 19% (Table 3, entry 1). Increas-
ing the  temperature  to  150 °C,  the  react ion was
completed after 30 min, but the proportion of the main product
3a was somewhat lower (78%), and another by-product 5a also
appeared in 7% (Table 3, entry 2). The target compound 3a
could be obtained in a yield of 61%. Using 3.5 equivalents of
diethyl phosphite at 125 °C for 1 h, the conversion was only
75%, but the expected product 3a was formed exclusively
(Table 3, entry 3). After a longer reaction time of 1.5 h,
by-product 4a also appeared in 22% (Table 3, entry 4). In the
reaction with cyclohexylamine, the same tendency was ob-
served (Table 3, entries 5–8), and the corresponding (cyclo-
hexylaminomethylene)bisphosphonate 3b was obtained in a
yield of 68% after column chromatography (Table 3, entry 6).
Finally, the three-component condensation of aniline, triethyl
orthoformate and diethyl phosphite was studied (Table 3,
entries 9–11). Applying 2 equivalents of phosphite, the reaction
was not complete, neither at 125 °C, nor at 150 °C (Table 3,
entries 9 and 10). Two types of imine intermediates (6a and 6b)
could be observed in the reaction mixture beside the expected
product 3c. These intermediates refer to the mechanism of the
condensation (see compounds I and V in Scheme 1, pathway
A). Previously, iminephosphonate 6b was only an assumed
intermediate [7], but now we could prove it by 31P NMR and
HRMS (Table 4). Increasing the amount of diethyl phosphite to
3 equivalents, the reaction was complete at 125 °C after 1 h, and
only 3c was formed with a yield of 82% (Table 3, entry 11). In
the cases discussed, no ethylated or formylated by-products (4
and 5, respectively) were formed. (Aminomethylene)bisphos-
phonates 3b and 3c were synthesized earlier in unoptimized ex-
periments to provide compounds 3b and 3c in yields of 36% [9]
and 53% [8], respectively. The former compound 3b was
characterized only by 1H NMR [9]. Compound 3c was also syn-
thesized under MW irradiation in a yield of 75% [31]. It can be
seen, that the refined MW-assisted method elaborated by us
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Table 3: The reactions of primary amines with triethyl orthoformate and diethyl phosphite.
Entry Y DEP
(equiv)
T (°C) t (h) Conversion
(%)a
Product composition (%)a Yield of 3
(%)c3 by-productsb
4 5
1 Bu 2 125 2 91 81 19 0 –
2 Bu 2 150 0.5 100 78 15 7 61 (3a)
3 Bu 3.5 125 1 75 100 0 0 –
4 Bu 3.5 125 1.5 90 78 22 0 –
5 c-Hex 2 125 2 76 83 17 0 –
6 c-Hex 2 150 0.5 100 88 10 2 68 (3b)
7 c-Hex 3.5 125 1 63 100 0 0 –
8 c-Hex 3.5 125 1.5 83 86 14 0 –
9 Ph 2 125 2 68 56d 0 0 36 (3c)
10 Ph 2 150 1 90 70d 0 0 52 (3c)
11 Ph 3 125 1 100 100 0 0 82 (3c)
aOn the basis of GC (entries 1–8) or on the basis of HPLC (entries 9–11). bThe by-products identified:
cIsolated yield. dThe following intermediates were also formed based on LC–MS:
Table 4: Spectral characterization of N-ethyl- (4) and N-formyl- (5) (aminomethylene)bisphosphonates and imine-type intermediates 6a and 6b.
Compounds δP in CDCl3 δP [lit.] [M + H]+found [M + H]+requires
4a 19.98 – 388.2020 388.2012
4b 20.63 – 414.2162 414.2169
5a 16.08 and 16.16(E and Z isomers)
15.69 and 15.98a
(E and Z isomers) [43] 388.1659 388.1649
5b 16.00 and 16.06(E and Z isomers) – 414.1797 414.1805
6a – – 197.1075 197.1073
6b 17.67 – 242.0936 242.0941
aIn CCl4.
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Scheme 7: Synthesis of tetramethyl (phenylaminomethylene)bisphosphonate.
Scheme 8: Synthesis of (dialkylaminomethylene)bisphosphonates.
may give the (aminomethylene)bisphosphonates 3b and 3c in
yields of 68% and 82%, respectively.
Next, the condensation of aniline with trimethyl orthoformate
and dimethyl phosphite was also performed (Scheme 7). In this
case, the reaction was complete after a 1 h heating at 110 °C
using 3.5 equivalents of dimethyl phosphite. After column chro-
matography, the corresponding product 7a was isolated in a
yield of 63%. At higher temperatures, decomposition was ob-
served.
In the next stage, the MW-assisted reaction of secondary amines
was studied with triethyl orthoformate and diethyl phosphite
(Scheme 8). The condensations were carried out applying
3.5 equivalents of diethyl phosphite at 125 °C for 1 h in the
absence of a catalyst and a solvent. In case of N-methylaniline,
4.5 equivalents of the P-reagent was necessary to attain
complete conversion (Table 5, entry 6). The corresponding
(dialkylaminomethylene)bisphosphonates (8a–g) were obtained
in yields of 65–86% after purification by chromatography
(Table 5, entries 1–7).
Finally, the three-component condensation of aniline, triethyl
orthoformate and dimethyl or dibutyl phosphite was studied
(Table 6, Figure 1). Using dimethyl phosphite, the reactions
were performed at 110 °C for 1 h, but in case of dibutyl phos-
phite, the conditions applied were the same as those in the con-
densations with diethyl phosphite (125–150 °C, 1 h). Using
2 equivalents of dialkyl phosphite, more or less transesterified
Table 5: Synthesis of (dialkylaminomethylene)bisphosphonates 8a–g.
Entry Y1 Y2 Yield (%)a
1 Et Et 86 (8a)
2 Bu Bu 68 (8b)
3 Bu Me 79 (8c)
4 c-Hex Me 72 (8d)
5 Bn Me 70 (8e)b
6c Ph Me 65 (8f)
7 -(CH2)2-O-(CH2)2- 81 (8g)d
aIsolated yield. bIt was synthesized in a yield of 61% [10]. c4.5 equiva-
lents of diethyl phosphonate was used.dIt was synthesized in a yield of
46% [4].
(aminomethylene)bisphosphonates (9–11 and 3c) were also
formed beside the expected (phenylaminomethylene)bisphos-
phonates 7a or 7b (Table 6,entries 1 and 6, 7). The transesteri-
fied by-products (9-11 and 3c) were indentified by GC–MS
(Figure 2) or LC–MS, and were proved by HRMS (Table 7).
The composition of the reaction mixture for the experiment
marked by Table 6, entry 6 was analyzed by 31P NMR (see
Figure 3). It was observed that increasing the quantity of dialkyl
phosphite, the proportion of the by-products was decreased, and
the condensations became more selective for the desired
product (7a or 7b) (Table 6, Figure 1). In the reaction with
dimethyl phosphite, the best result was achieved using
20 equivalents of the P-reagent, but in case of dibutyl phosphite,
a 15-fold excess was sufficient (Table 6, entries 5 and 10).
Beilstein J. Org. Chem. 2016, 12, 1493–1502.
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Table 6: Condensation of aniline, triethyl orthoformate and dimethyl or dibutyl phosphite.
Entry R Dialkyl phosphite (equiv) T (°C) Product composition (%)a
7 9 10 11 3c
1 Me 2 110 14 36 36 11 3
2 Me 6 110 54 37 9 0 0
3 Me 10 110 77 18 5 0 0
4 Me 15 110 87 13 0 0 0
5 Me 20b 110 91 9 0 0 0
6 Bu 2 150 19 23 29 26 3
7 Bu 2 125 54 33 10 3 0
8 Bu 6 125 82 16 2 0 0
9 Bu 10 125 93 7 0 0 0
10 Bu 15b 125 95 5 0 0 0
aOn the basis of GC (entries 1–5) or on the basis of HPLC (entries 6–9). bThe product composition has not changed using a larger excess of dialkyl
phosphite.
Figure 1: Effect of the quantity of dimethyl phosphite (DMP) on the product composition (from Table 6, entries 1–5.)
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Figure 2: GC–MS chromatogram for the condensation of aniline, triethyl orthoformate and 2 equivalents of dimethyl phosphite (from the exp. marked
by Table 6, entry 1).
Figure 3: 31P NMR spectrum for the condensation of aniline, triethyl orthoformate and 2 equivalents of dibutyl phosphite (from the exp. marked by
Table 6, entry 6).
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Table 7: Mass spectral characterization of (aminomethylene)bisphosphonates.
R = Me (b) R = Bu (c)
[M + H]+found [M + H]+requires [M + H]+found [M + H]+requires
7 324.0760 324.0760 492.2648 492.2638
9 338.0921 338.0917 464.2329 464.2325
10 352.1072 352.1073 436.2011 436.2012
11 366.1231 366.1230 408.1711 408.1699
3c 380.1382 380.1386 380.1382 380.1386
Conclusion
In summary, we have developed a facile, solvent- and catalyst-
free MW-assisted method for the synthesis of (amino-
methylene)bisphosphine oxides (AMBPOs) and (amino-
methylene)bisphosphonates by the condensation of a primary or
secondary amine, an orthoformate, and diphenylphosphine
oxide or a dialkyl phosphite. This method is a novel approach
for the preparation of AMBPOs and an optimized process for
the synthesis of (aminomethylene)bisphosphonates. Twenty-
two derivatives were isolated and characterized, except two, all
of them are new compounds. Furthermore, a few intermediates
supporting the mechanism of the condensation, and several
by-products were also identified.
Supporting Information
Experimental procedures, characterization data, details of
the NMR structural determination of all products and
copies of 31P, 1H, and 13C NMR spectra for all compounds
synthesized are presented in Supporting Information File 1.
Supporting Information File 1
Experimental, NMR spectra.
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